Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38666490 | 0.90 | EGFR (0.52) | EGFRALDH1A1KDM4EHPGDGAA | |
| SCHEMBL16674798 | 0.89 | EGFR (0.51) | EGFRALDH1A1KDM4EHPGDGAA | |
| SCHEMBL15068575 | 0.88 | EGFR (0.53) | EGFRALDH1A1KDM4EHPGDGAA | |
| SCHEMBL38666633 | 0.87 | EGFR (0.48) | EGFRALDH1A1KDM4EHPGDMEN1 | |
| SCHEMBL16764335 | 0.86 | TSHR (0.53) | EGFRALDH1A1KDM4EHPGDGAA | |
| SCHEMBL956204 | 0.86 | EGFR (0.55) | EGFRALDH1A1KDM4EHPGDGAA | |
| SCHEMBL21586237 | 0.84 | EGFR (0.54) | EGFRALDH1A1KDM4EHPGDGAA | |
| SCHEMBL10931099 | 0.84 | EGFR (0.51) | EGFRALDH1A1KDM4EHPGDGAA | |
| SCHEMBL2035471 | 0.82 | EGFR (0.48) | EGFRALDH1A1KDM4EHPGDGAA | |
| SCHEMBL5847756 | 0.82 | MIF (0.48) | EGFRALDH1A1KDM4EHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50083-E1 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2024-08-20 | — | — | US | disclosed |
| US-11597725-B2 | URAT1 inhibitor for promoting uric acid excretion | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-03-07 | — | — | US | disclosed |
| CN-108484600-B | URAT1 inhibitors for promoting uric acid excretion | 江苏新元素医药科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| EP-3543240-B1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3632904-B1 | URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-04-20 | — | — | EP | disclosed |
| EP-3632904-B1 | URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-20200262832-A1 | URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| EP-3632904-A1 | URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| WO-2011075643-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| EP-2260020-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597725-B2 | URAT1 inhibitor for promoting uric acid excretion | SLC10A6, SLC10A1, SLC28A1 | EGFR 4309/4885ALDH1A1 326/4885KDM4E 4052/4885 |
| US-10875865-B2 | URAT1 inhibitor and use thereof | SLC14A1, SLC10A6, SLC10A1 | EGFR 4546/4885ALDH1A1 356/4885KDM4E 4224/4885 |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | EGFR 4092/4885ALDH1A1 238/4885KDM4E 305/4885 |
| US-20200262832-A1 | URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION | SLC10A6, SLC10A1, SLC28A1 | EGFR 4309/4885ALDH1A1 326/4885KDM4E 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.